|
|
|
|
|
|
|
|
|
|
|
26.11.25 - 13:57
|
Medicare Secures 71% Price Cut On Novo′s Anti-Obesity Drug As Part Of Broad Affordability Push (ZeroHedge)
|
|
|
Medicare Secures 71% Price Cut On Novo's Anti-Obesity Drug As Part Of Broad Affordability Push
The Trump administration is laser-focused on "Operation Affordability," aiming to drive down the cost of food and healthcare ahead of the midterm election cycle.
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced a savings of 44%, or $12 billion, from last year's negotiated Medicare spending on 15 drugs used to treat severe chronic conditions and cancer.
Of those price cuts, CMS negotiated a 71% discount on GLP-1 medication, including Ozempic and Wegovy, for Medicare patients.
Other significant reductions include a 50% cut for Pfizer's Ibrance, a 48% drop for the prostate-cancer drug Xtandi, and a 73% reduction for GSK's Trelegy Ellipta.
Here's more from CMS:
The Maximum Fair Prices (MFPs) for these 15 drugs will become effective January 1, 2027, bringing the total number of negotiated drugs to 25 when combined with the 10 previously negotiated drugs with...
|
|
|
26.11.25 - 11:33
|
Pfizer Hold (DPA-AFX)
|
|
|
HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Pfizer auf "Hold" mit einem Kursziel von 25 US-Dollar belassen. Nach der jährlichen Branchenveranstaltung von Berenberg unter anderem mit Pfizer-Finanzchef Dave Denton sowie Informationsveranstaltungen ......
|
|
|
|
|
26.11.25 - 07:03
|
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (month 48) in all age groups, confirming compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. Pfizer and Valneva entered into a collaboration agreement in April 2020 for the development and commercialization of VLA15 by Pfizer....
|
|
|
26.11.25 - 06:30
|
Escobar: The European Matryoshka Of Irrelevance (ZeroHedge)
|
|
|
Escobar: The European Matryoshka Of Irrelevance
Authored by Pepe Escobar,
The EU/NATO combo cannot but play the role of pathetic yapping chihuahuas. That's the price you pay for a matrioshka of supreme stupidity.
No one ever lost money betting on the politically suicidal instincts of post-Orwellian EU – that acronym for a virtual Europe.
Call them juvenile bipolar psychos or a bunch of yapping chihuahuas: no Jupiterian or Mercurial voice of reason has been capable to impart to the “leadership” in Brussels and their vassals in most European capitals – yes, there are healthy exceptions – that losers in wars do not dictate terms.
And still those War Council luminaries – with a special starring role for the toxic Pfizer Medusa and her Estonian sidekick unable to even manage a herring stall in the Baltics – insist that essentially the mega-corrupt gang in Kiev must prevail, to the last Ukrainian dead, and on top of it dictate the final terms of their non-surrender.
Reality begs to di...
|
|
|
26.11.25 - 00:01
|
"CEO Ready" Co-Authors on Turnover, Co-CEO Pros and Cons (Bloomberg)
|
|
|
Byron Loflin, Nasdaq's Global Head of Board Advisory, and Mark Thompson, executive coach to leaders at Google, Apple and Pfizer, discuss their new book “CEO Ready,” including what makes an effective leader and the pros and cons of the co-CEO model. They speak with Romaine Bostick and Katie Greifeld on “The Close.” (Source: Bloomberg)...
|
|
|
24.11.25 - 13:03
|
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire EN)
|
|
|
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being developed with Pfizer Inc. (NYSE: PFE) as a potential monotherapy for estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting.* Ongoing studies are also evaluating vepdegestrant as a monotherapy and as part of combination therapy for ER+/HER2- breast cancer....
|
|
|
|
|
|
|
|
|
|
|
|
|
20.11.25 - 20:00
|
Pfizer and Tris reach settlement with Texas over ADHD drug allegations (PBR)
|
|
|
This is in breach of the Texas Health Care Program Fraud Prevention Act. The ADHD drugs case centred on the medication Quillivant XR, provided to children on Medicaid.
The post Pfizer and Tris reach settlement with Texas over ADHD drug allegations appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
20.11.25 - 12:12
|
Pfizer and Tris agree with Texas over ADHD drug allegations (PBR)
|
|
|
This is in breach of the Texas Health Care Program Fraud Prevention Act. The ADHD drugs case centred on the medication Quillivant XR, provided to children on Medicaid.
The post Pfizer and Tris agree with Texas over ADHD drug allegations appeared first on Pharmaceutical Business review....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
